Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D00527 (Nedocromil sodium)
 190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the effects of nedocromil sodium and sodium cromoglycate on early and late bronchial responses, the airway inflammation associated with the late response to inhaled Ascaris suum antigen in allergic sheep in vivo, and the antigen-induced contractile responses of sheep tracheal smooth muscle in vitro. In addition, we examined the effect of nedocromil sodium on the development of antigen-induced airway hyper-responsiveness in this model. Pretreatment with either nedocromil sodium or sodium cromoglycate was effective in blocking antigen-induced early and late responses in allergic sheep. Both drugs also prevented the influx of eosinophils into the airways as assessed by bronchoalveolar lavage, observed during the late response in this model. No difference in drug potency was observed in vivo, but in vitro nedocromil sodium was 10-fold more potent than sodium cromoglycate against antigen-induced contractions of sheep tracheal smooth muscle. Nedocromil sodium was effective in blocking antigen-induced late responses and the subsequent development of airway hyper-responsiveness irrespective of whether the drug was given before antigen challenge or after the immediate response to antigen but before the late response. These findings indicate that nedocromil sodium is effective in the sheep model of asthma and therefore may be beneficial in the treatment of reversible obstructive airway disease in man.
 ...
PMID:Effect of nedocromil sodium on antigen-induced airway responses in allergic sheep. 254 69

Nedocromil sodium (Tilade) is a novel pyranoquinoline dicarboxylic acid, developed for the treatment of reversible obstructive airway disease (ROAD). The drug exhibits specific anti-inflammatory properties when administered topically to the airways. These properties are illustrated by the activity of the drug in a number of in vitro and in vivo models. Thus, in vitro, nedocromil sodium inhibits activation of, and mediator release from, a wide range of inflammatory cells (neutrophils, eosinophils, macrophages/monocytes, mast cells and platelets) in both animals and man, initiated by either specific or non-specific stimuli. In vivo, the drug is effective in models of anaphylactic bronchospasm, increased vascular permeability, cellular influx, late reaction and bronchial hyperreactivity. Although as yet the mechanism of action has not been fully clarified, nedocromil sodium (Tilade) has demonstrated unequivocal efficacy in the treatment of ROAD in controlled therapeutic studies of up to twelve weeks in duration.
 ...
PMID:Nedocromil sodium (Tilade): a review of preclinical studies. 255 33

This study evaluated the airway effects of nedocromil sodium in the sheep model of allergic bronchoconstriction. Nedocromil sodium provided statistically significant protection against both reflex- and mediator-induced bronchoconstriction in allergic sheep as assessed by bronchial responses to inhaled bradykinin and platelet-activating factor, respectively. When administered before antigen challenge, nedocromil sodium blocked both the immediate and late asthmatic response and prevented the subsequent increase in airway hyperresponsiveness. The protective effect of nedocromil sodium against the antigen-induced late response was associated with a significant decrease in the number of airway eosinophils measured by bronchoalveolar lavage. Although nedocromil sodium has no direct bronchodilatory activity, it prevented antigen-induced contractions in sheep tracheal smooth muscle in vitro. These results suggest that nedocromil sodium is active in the sheep model of allergic bronchoconstriction and may be useful in the treatment of reversible obstructive airway disease in human beings.
 ...
PMID:Effect of nedocromil sodium on specific mediator- and antigen-induced airway responses in allergic sheep. 839 23